Citadel Advisors
ARIA

Citadel Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Citadel Advisors’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-60,400
Closed -$751K – 8514
2016
Q4 		$751K Sell
60,400
-22,400
-27% -$270K ﹤0.01% 4272
2016
Q3 		$1.13M Buy
82,800
+26,400
+47% +$265K ﹤0.01% 3674
2016
Q2 		$417K Buy
56,400
+12,800
+29% +$96K ﹤0.01% 4743
2016
Q1 		$279K Sell
43,600
-40,600
-48% -$228K ﹤0.01% 5195
2015
Q4 		$526K Buy
84,200
+7,500
+10% +$49.2K ﹤0.01% 4405
2015
Q3 		$448K Sell
76,700
-5,600
-7% -$43.1K ﹤0.01% 4956
2015
Q2 		$681K Buy
82,300
+38,700
+89% +$342K ﹤0.01% 4511
2015
Q1 		$359K Sell
43,600
-84,100
-66% -$622K ﹤0.01% 5404
2014
Q4 		$877K Buy
127,700
+11,300
+10% +$70.7K ﹤0.01% 3922
2014
Q3 		$629K Buy
116,400
+14,800
+15% +$86.4K ﹤0.01% 4329
2014
Q2 		$647K Sell
101,600
-118,900
-54% -$818K ﹤0.01% 4059
2014
Q1 		$1.78M Buy
220,500
+79,500
+56% +$619K ﹤0.01% 2782
2013
Q4 		$962K Buy
141,000
+104,200
+283% +$563K ﹤0.01% 3258
2013
Q3 		$677K Sell
36,800
-29,000
-44% -$563K ﹤0.01% 3499
2013
Q2 		$1.15M Buy
+65,800
New +$1.17M ﹤0.01% 3044

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Citadel Advisors's ARIA Position: Q1 2017 in Review

Citadel Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 180,772 shares — an estimated $2.25M sold.

Citadel Advisors first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $5.77M in Q1 2014. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Citadel Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Citadel Advisors sold 180,772 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $2.25M.
  • Citadel Advisors first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Citadel Advisors's Ariad Pharmaceuticals Inc position peaked at $5.77M in Q1 2014.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.